Howard C. Herrmann, MD, principal investigator of the SMART trial, discussed his team's research on self-expanding vs. balloon-expandable TAVR valves in patients with small annuli. 

While most TAVR-related reinterventions occurred in the first year after treatment, most SAVR-related reinterventions occurred in years two through five. The team's full analysis is available in JACC: Cardiovascular Interventions.

TAVR is noninferior to SAVR when treating low-risk patients, according to new data presented at ACC.24. In fact, it is associated with multiple benefits over surgery.

The SMART trial included one-year data from TAVR patients randomized to receive either a self-expanding Evolut valve or a balloon-expandable Sapien 3 valve. All patients presented with symptomatic severe aortic stenosis and a small aortic annulus. A whopping 87% of participants were women. 

Transcatheter pulmonary valve replacement is still linked to certain risks, researchers noted, but new data confirm it is a safe, effective treatment option for patients with severe PR. 

San Francisco-based Osso VR and the American College of Cardiology have collaborated on advanced LAAO simulations. The two groups first started working together back in 2022. 

Less than two months after an FDA advisory panel voted in favor of approval, the transcatheter edge-to-edge repair system can now be sold and marketed in the United States.

The long-term impact of moderate PPM remains unclear. To learn more, researchers explored dozens of different studies from over the years, sharing their work in the Journal of the American Heart Association.